Ophira Ginsburg has joined NYU Langone’s Perlmutter Cancer Center as director of its new High Risk Program, which identifies, studies and cares for patients with hereditary syndromes that increase cancer risk.
In a unanimous vote, the FDA Oncologic Drugs Advisory Committee advised the agency to accept the metric of “minimal residual disease,” or MRD, as a basis for accelerated approvals of therapies in all settings of multiple myeloma.
